Nirvana Life Sciences Inc. reported earnings results for the second quarter and six months ended October 31, 2022. For the second quarter, the company reported net loss was CAD 0.274772 million compared to CAD 0.259734 million a year ago. Basic loss per share from continuing operations was CAD 0.01 compared to CAD 0.01 a year ago.
For the six months, net loss was CAD 0.549017 million compared to CAD 0.368916 million a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.01 a year ago.